stoxline Quote Chart Rank Option Currency Glossary
  
Esperion Therapeutics, Inc. (ESPR)
2.68  0.06 (2.29%)    03-28 16:00
Open: 2.63
High: 2.8
Volume: 8,161,413
  
Pre. Close: 2.62
Low: 2.54
Market Cap: 457(M)
Technical analysis
2024-03-28 4:51:11 PM
Short term     
Mid term     
Targets 6-month :  3.53 1-year :  4.13
Resists First :  3.02 Second :  3.53
Pivot price 2.26
Supports First :  2.34 Second :  1.91
MAs MA(5) :  2.58 MA(20) :  2.3
MA(100) :  2.09 MA(250) :  1.63
MACD MACD :  0 Signal :  -0.1
%K %D K(14,3) :  71.8 D(3) :  72.6
RSI RSI(14): 61.1
52-week High :  3.33 Low :  0.69
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ESPR ] has closed below upper band by 7.6%. Bollinger Bands are 12.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.8 - 2.81 2.81 - 2.82
Low: 2.51 - 2.52 2.52 - 2.54
Close: 2.66 - 2.68 2.68 - 2.7
Company Description

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Headline News

Thu, 28 Mar 2024
Does Esperion Therapeutics Inc (ESPR) Have What it Takes to be in Your Portfolio Thursday? - InvestorsObserver

Thu, 28 Mar 2024
ESPERION THERAPEUT Trade Ideas — BX:0ET — TradingView - TradingView

Wed, 27 Mar 2024
FY2026 EPS Estimates for Esperion Therapeutics, Inc. Lowered by HC Wainwright (NASDAQ:ESPR) - MarketBeat

Wed, 27 Mar 2024
Esperion Therapeutics (NASDAQ:ESPR) Shares Gap Up to $2.70 - MarketBeat

Wed, 27 Mar 2024
Do Traders Think Esperion Therapeutics Inc (ESPR) Can Keep Climbing Wednesday? - InvestorsObserver

Tue, 26 Mar 2024
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Consensus Recommendation of “Hold” by Brokerages - Defense World

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 185 (M)
Shares Float 184 (M)
Held by Insiders 0.8 (%)
Held by Institutions 41.6 (%)
Shares Short 16,950 (K)
Shares Short P.Month 20,070 (K)
Stock Financials
EPS -2.03
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -3.85
Profit Margin -179.9 %
Operating Margin -131.4 %
Return on Assets (ttm) -42.9 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 71.4 %
Gross Profit (p.s.) 0
Sales Per Share 0.62
EBITDA (p.s.) -0.84
Qtrly Earnings Growth 0 %
Operating Cash Flow -135 (M)
Levered Free Cash Flow -107 (M)
Stock Valuations
PE Ratio -1.33
PEG Ratio -0.3
Price to Book value -0.7
Price to Sales 4.26
Price to Cash Flow -3.67
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android